Roivant Says Brepocitinib Met Primary, All Key Secondary Endpoints In Two Phase 3 Non-Infectious Uveitis Trials; Plans sNDA In H1 2027
Share
Why It Matters
Roivant's medicine passed big tests for eye inflammation. This is good news about whether the drug works and is safe.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.